TY - JOUR
T1 - Molecular mechanisms of action of ribavirin
AU - Patterson, Jean L.
AU - Fernandez-Larsson, Roberto
N1 - Funding Information:
This work was supported by U.S. Army grant no. DAMDI7-87-C-7004 and grant no. UOI-AI-25934 from the National Institutes of Health. R. Fernandez-Larsson was supported in part by training grant no. 5T326AI07245 from the National Institutes of Health.
PY - 1990/11
Y1 - 1990/11
N2 - Ribavirin (l-β-d-ribofuranosyl-l,2,4-triazole-3-carboxamide) is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. This antiviral agent was approved by the U.S. Food and Drug Administration in 1986 for use as an aerosol for infants with serious infections due to respiratory syncytial virus. Ribavirin is and has been under clinical investigation for activity against a variety of viral illnesses, including those due to influenza virus, Lassa fever virus, Hantaan virus, and human immunodeficiency virus (HIV). There has been a great deal of clinical interest in the utilization of ribavirin for treatment of infections due to HIV. It has been reported to slow the development of AIDS in HIV-infected patients. We describe here the major mechanisms of action of this newly licensed antiviral agent.
AB - Ribavirin (l-β-d-ribofuranosyl-l,2,4-triazole-3-carboxamide) is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. This antiviral agent was approved by the U.S. Food and Drug Administration in 1986 for use as an aerosol for infants with serious infections due to respiratory syncytial virus. Ribavirin is and has been under clinical investigation for activity against a variety of viral illnesses, including those due to influenza virus, Lassa fever virus, Hantaan virus, and human immunodeficiency virus (HIV). There has been a great deal of clinical interest in the utilization of ribavirin for treatment of infections due to HIV. It has been reported to slow the development of AIDS in HIV-infected patients. We describe here the major mechanisms of action of this newly licensed antiviral agent.
UR - http://www.scopus.com/inward/record.url?scp=0025203460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025203460&partnerID=8YFLogxK
U2 - 10.1093/clinids/12.6.1139
DO - 10.1093/clinids/12.6.1139
M3 - Article
C2 - 2267489
AN - SCOPUS:0025203460
VL - 12
SP - 1139
EP - 1146
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 6
ER -